Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro

Clinical and Experimental Metastasis

Volumn 17, Issue 2, 1999, Pages 131-140

  Dolo, Vincenza ^a   D'Ascenzo, Sandra ^a   Violini, Stefania ^a   Pompucci, Lorena ^a   Festuccia, Claudio ^a   Ginestra, Angela ^a   Vittorelli, M Letizia ^b   Canevari, Silvana ^c   Pavan, Antonio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Membrane vesicles; Metalloproteinases; Ovarian cancer

Indexed keywords

ALPHA FOLATE RECEPTOR; CANCER ANTIBODY; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UROKINASE;

ADULT; ARTICLE; CARCINOMA CELL; CELL INTERACTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE VESICLE; METASTASIS; OVARY CARCINOMA; PROTEIN DEGRADATION; TUMOR GROWTH; WESTERN BLOTTING; ZYMOGRAPHY;

ADENOCARCINOMA, PAPILLARY; BLOTTING, WESTERN; CELL MEMBRANE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; METALLOENDOPEPTIDASES; MICROSCOPY, ELECTRON; MIDDLE AGED; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0032801787     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006500406240     Document Type: Article

References (36)

1. Young TN, Rodriguez GC, Rinehart AR et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89-99.
2. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996; 8: 731-8.
3. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
4. Taylor DD, Black PH. Shedding of plasma membrane fragments. Neoplastic and developmental importance. In: Steinberg M (ed) Developmental Biology. New York: Plenum Press 1986; 33-57.
5. Doljanski F, Kapeller M. Cell surface shedding-The phenomenon and its possible significance. J Theor Biol 1976; 62: 253-70.
6. Dolo V, Ginestra A, Cassarà D et al. Selective localization of MMP-9, bl integrin and HLA I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 1998; 58: 4468-74.
7. Taylor DD, Black PH. Inhibition of macrophage 1a antigen expression by shed plasma membrane vesicles from metastatic murine melanoma cells. J Natl Cancer Inst 1995; 74: 859-63.
8. Tarin D. Epithelial-Mesenchymal Interactions in Carcinogenesis. London: Academic Press 1972; 228-89.
9. Van Blitterswijk WJ, Dever G, Krol J et al. Comparative lipid analysis of purified plasma membranes and shed extracellular membrane vesicles from normal murine thymocytes and leukemia GSRL cells. Biochim Biophys Acta 1986; 68: 495-504.
10. Chiba I, Jin R, Hamada J, Hosokawa M et al. Growth-associated shedding of a tumor antigen (CE7) detected by a monoclonal antibody. Cancer Res 1989; 49: 3972-75.
11. Dolo V, Ginestra A, Ghersi G, Nagase H, Vittorelli ML. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol 1994; 26: 173-80.
12. Dolo V, Adobati E, Canevari S et al. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis 1995; 13: 277-86.
13. Dolo V, Pizzurro P, Ginestra A et al. Inhibitory effects of vesicles shed by human breast carcinoma cells on lymphocyte 3H-thymidine incorporation, are neutralized by anti-TGF-b antibodies. J Submicrosc-Cytol Pathol 1995; 2: 535-41.
14. Miotti S, Canevari S, Ménard S, Mezzanzanica D et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987; 3: 297-303.
15. Coney LR, Tomasetti A, Carayannopoulos L et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991; 51: 6125-32.
16. Cambell IG, Jones TA, Foulkes WD et al. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51: 5329-38.
17. Mantovani LT, Miotti S, Ménard S et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 1994; 30A: 363-9.
18. Dolo V, Ginestra A, Violini S, Miotti S et al. Ultrastructural and phenotypic characterization of CABA 1, a new human ovarian cancer cell line. Oncol Res 1997; 9: 129-38.
19. Thompson E, Nakamura S, Shima T et al. Supernatants of acquired immunodeficiency syndrome-related Kaposi's sarcoma cells induce endothelial cell chemotaxis and invasiveness. Cancer Res 1991; 51: 2670-1.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-day binding. Anal Biochem 1976; 72: 248-54.
21. Albini A, Iwamoto Y, Kleinman HK et al. A rapid in vivo assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
22. Albini A, Melchiori A, Garofalo A et al. Matrigel promotes retinoblastoma cell growth in vitro and in vivo. Int J Cancer 1992; 52: 234-40.
23. Azzam HS, Thompson E. Collagen-induced activation of the Mr 72,000 type IV collagenase in normal and malignant fibroblast cells. Cancer Res 1992; 52: 4540-4.
24. Festuccia C, Dolo V, Guerra F et al. Plasminogen activator system modulates invasive capability and cell proliferation in prostatic tumor cells. Clin Exp Metastasis 1998; 16(6): 513-28.
25. Moser TL, Young TN, Rodriguez GC et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56: 552-9.
26. Dvorak HF, Quay SC, Orestein NS et al. Tumor shedding and coagulation. Science 1981; 212: 923-4.
27. Buist MR, Molthoff CF, Kenemans P et al. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. J Clin Pathol 1995; 48: 631-6.
28. Toffoli G, Cernigoi C, Russo A et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74: 193-8.
29. Rose JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: Physiologic and clinical implications. Cancer 1994; 73: 2432-43.
30. Kleiner D Jr, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993; 5: 891-7.
31. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 7: 161-95.
32. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-5.
33. Zucker S, Moll UM, Lysik RM et al. Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells. Int J Cancer 1990; 45: 1137-42.
34. Naylor MS, Stamp GW, Davies BD et al. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50-6.
35. Ginestra A, Monea S, Seghezzi G et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 1997; 272: 17216-221.
36. Zucker S, Lysik RM, Zarrabi MH et al. Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140-6.